
An experimental treatment showed promising early results for reducing the risk of dementia related to Alzheimer’s for asymptomatic patients who are expected to develop the neurodegenerative disease.
Researchers followed a small group of 22 patients who had genetic mutations that cause the overproduction of amyloid in the brain.